$4.5m funding round

December 18, 2018

CAMBRIDGE, 18th December  2018 -

Cambridge Cancer Genomics (CCG.ai), today announced they have raised $4.5m to build a precision AI platform for personalised cancer medicine.

Capital was raised from a host of Silicon Valley investors, including Jerry Yang’s AME Cloud Ventures, Refactor Capital, Romulus Capital and Y Combinator, to support growing clinical operations in the UK, US and Singapore. In the US, CCG have partnered with the Comprehensive Blood and Cancer Centre in Bakersfield, who invested $750,000 along with over 4,000 clinical samples, to bring a new type of cancer therapy to patients.

This seed financing has enabled us to set up and develop our R&D base in Cambridge, UK. Funds will continue to be used to develop our precision AI platform for personalised cancer cancer. We will also embark on further clinical trials to investigate the use of longitudinal liquid biopsies in predicting tumour evolution in response to cancer treatment.” said Dr. John Cassidy, co-founder and CEO.


When you drill down into the DNA changes behind cancer, you quickly find that no two tumours are the same. To apply cancer therapies more successfully to any given tumour, we need a deeper understanding of what exactly has gone wrong in each case at a molecular level. The tools we are building at we’re developing at CCG will have widespread applications, from identifying targets for new therapy development, to deciding which personalised approach is best for a given patient.” says Dr. Harry Clifford, co-founder and CTO.


About Cambridge Cancer Genomics

Cambridge Cancer Genomics (CCG.ai) is a Y Combinator backed startup building the underlying tools to empower oncologists to make the best therapeutic decisions for their patients. Their precision AI platform, OncOS, is fast becoming the global open standard for next generation sequencing analysis and clinical decision support in cancer medicine. By focussing on machine learning based analytics of serial liquid biopsy samples, CCG.ai is building predictive models to understand how tumours evolve and how this can impact on response to therapy. As this knowledge base of tumour genomic evolution increases, OncOS will become the operating system for personalised cancer medicine. At CCG.ai, our mission is to ensure every patient gets the right drug, at the right time, to beat their cancer.

Press Enquiries

For more details, or to request an interview, please contact: Press@CCG.ai